TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Fetal Brain Asymmetry: in Utero and Early Neonatal Follow up

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18-42 years old pregnant women~* 19-30 weeks of pregnancy~* No medical history of chronic disease~* No medical history of drug therapy~* No other findings on ultrasound examination~* Low risk pregnancy~Exclusion Criteria:~* Fetal malformation~* Chronic maternal disease~* Fetal chromosomal aberration~* suspected fetal infection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- fetal ventricle brain asymmetry (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects age ≤18 years~2. Subjects scheduled for cardiac surgery with cardiopulmonary bypass~Exclusion Criteria:~1. Subjects with abnormal creatinine clearance (\<90 ml/min/1.7m2) as measured by the Schwartz formula~2. Subjects with known cystic kidney disease or posterior ureteral valves (subjects with solitary kidney, single multicystic/dysplastic kidney, hydronephrosis will not be excluded if renal function is preserved)~3. Subjects with known metabolic disorder~4. Premature infants born \<30 weeks gestation and \<30 days old due to risk of intraventricular hemorrhage~Subjects in severe cardiogenic shock post-operative requiring extra-corporeal membrane oxygenation (ECMO) or left ventricular assist device (LVAD) will be withdrawn from the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Sodium bicarbonate (Type: EXPERIMENTAL): At the start of the surgery, the patient will receive NaHCO3 as a continuous infusion of D5% 1/3NS + 100 meq/L NaHCO3 + 20 meq/L KCl at maintenance IVF (solution contains \~154 meq of sodium which is equivalent to normal saline). The NaHCO3 infusion will continue for the first 24 hours after the discontinuation of CPB. After 24 hours of receiving the NaHCO3 infusion, the IVF administered to the patient will be the standard solutions used in the PICU at CCMC.
- Sodium Chloride (Type: ACTIVE_COMPARATOR): At the start of surgery, patients in the control arm will receive D5% Normal Saline + 20 meq/L KCl at maintenance IVF. After 24 hours, standard IVF, not containing NaHCO3 or Na acetate will be administered for the duration of the PICU stay as required, determined by the clinicians primarily caring for the patient postoperatively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the CR Plug (Allograft) for the Treatment of a Cartilage Injury in the Knee.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Skeletally mature~* Have one symptomatic score International Cartilage Repair Score (ICRS) grade 3a, 3b, 3c, 3d, 4a, 4b articular cartilage lesion less than 2.5 cm involving the Medial Femoral Condyle (MFC) or Lateral Femoral Condyle (LFC). Symptoms must include pain, pain with weight bearing and squatting, locking of joints, and/or swelling~* Functional meniscal tissue (defined as 5 mm or more width)~* A score of = or greater than 4 on the VAS questionnaire~Exclusion Criteria:~* Associated tibial or patellar articular cartilage defect greater than 2 ICRS~* Osteoarthritis of either knee~* Mechanical axis malalignment of greater than 5 degrees~* Patellofemoral incongruity of Merchant view~* One or more multiple defects greater than 2.5 cm~* Osteochondritis dissecans (OCD) with depth of bone loss greater than 4 mm~* Ligament treatments in the affected knee within one yer prior to current study~* Previous surgical meniscus treatments in the affected knee in the last 6 months~* Less than 5 mm of meniscal tissue in ipsilateral compartment of study treatment~* Use of any investigational therapy with in 30 days prior to the first visit~* Corticosteroid or viscosupplementation within the past 3 months~* A score of 3 or less on the VAS Questionnaire~* Active gout or pseudogout or systemic inflammatory condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CR Plug (Type: OTHER): Placement of allograft CR Plug in primary injury site

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: First in Human Study to Test the Safety and Preliminary Efficacy of PPSGG in Patients With Anti-MAG Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a confirmed diagnosis of monoclonal IgM associated with MGUS with anti-MAG activity (titer of \> 10'000 BTU) and demyelinating neuropathy defined by electrophysiological criteria according to EFNS/PNS PDN guideline, 2010.~* Clear clinical signs of disability~* Adequate hepatic and renal function~Exclusion Criteria:~* Patients with total serum IgM levels \>30 g.~* Hematological malignancy, prior malignancy of any organ system (except BCC)~* Prior immunosuppression: No IVIG in previous 3 months, no previous cyclophosphamide or biologicals in prior 6 months.~* Other neurological, neuromuscular, rheumatologic or orthopedic condition with significant impact on the capabilities of walk preventing evaluation of neurological scores

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PPSGG (Type: ACTIVE_COMPARATOR): sterile liquid, one 1-hour infusion in SAD and multiple infusions in MAD. In SAD multiple cohorts being tested. Dosage and regime in MAD to be defined based on SAD outcome.
- Placebo (Type: PLACEBO_COMPARATOR): standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: H+ Mobilization With Dialysate Bicarbonate Variation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must be 18 years or older,~2. Have been on dialysis for at least 1 year,~3. Be stable on treatment (i.e., without frequent changes in their dialysis prescription, or recent hospitalizations),~4. Be reasonably nourished (serum albumin \> 3.5 g/dl and not currently receiving oral nutritional supplement through DCI).~5. Self-reported urine output of \<200 cc/day~6. Functioning arteriovenous fistulas or grafts for dialysis access~7. Currently dialyzing at a dialysate \[HCO3-\] of 33-37 mEq/L.~Exclusion Criteria:~1. Pregnancy,~2. Acute illnesses of any kind,~3. Hospitalization in the prior 3 months (except for vascular access related),~4. Significant congestive heart failure, liver or lung failure.~5. Pre-dialysis blood \[HCO3-\] \<19 mEq/L) (to reduce the risk of metabolic acidosis )

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bicarb Variation (Type: OTHER): Variation in dialysis bicarbonate, lowered to 30 mEq/L for week 2 of 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: RIsk of Apoplexia Cerebri in CLOpidogrel Non-responders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted to neurological department with stroke signs om CT or MRI or history consistent with stroke and gives clopidogrel 75 mg as prophylactic treatment.~Exclusion Criteria:~* cancer diagnosis Other anti platelet treatment

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Stroke (Type: None): clopidogrel 75 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Retreatments With Intravitreal Bevacizumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \* Any visual acuity~  * OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid.~ * Active angiogram leakage~Exclusion Criteria:~* \* Basal Inflammatory disease~  * Endoftalmitis history~ * Lesions bigger than 5400 u or with scarring greater than 50% of lesion.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Interest of Pregabalin (Lyrica) on the Treatment of Reflex Earache in Head and Neck Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* referred otalgia~* ENT cancer~* ASA score 1,2 or 3~* understanding protocol~* information and free and informed consent~Exclusion Criteria:~* ASA score 4 et 5~* allergy or intolerance of pregabalin~* creatinin clearance inferior of 50ml/min (Cockcroft formula)~* liver failure~* cardiac failure~* history epilepsy~* ant hyperalgesic treatment~* minor or disabled adult~* intellectual disabilities that prevent the understanding of the protocol~* uncooperative patient~* pregnant women~* patient participating in another research protocol~* lactose intolerant patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pregabalin group (Type: EXPERIMENTAL): None
- Placebo group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Enrollment on study is within 5 days (including weekends) of starting second-line therapy~* aGVHD grade 2 or higher at time of enrollment; patients with late acute and recurrent aGVHD are permitted~* Donor lymphocyte induced aGVHD is permitted ONLY IF donor lymphocyte infusion given for mixed chimerism and not for progression of disease and meeting all other inclusion and exclusion criteria will be eligible~* Corticosteroid refractory or corticosteroid dependent aGVHD~  * Corticosteroid refractory aGVHD is defined as worsening of aGVHD after 3 days of systemic corticosteroids (minimum dose of 1 mg/kg), or no improvement after 7 days of systemic corticosteroids (minimum dose of 1 mg/kg)~ * Corticosteroid dependent aGVHD is defined as recurrence of aGVHD (grade 2 or higher) during corticosteroid taper and prior to reaching 50% of initial starting dose of corticosteroids~* Informed consent form~Exclusion Criteria:~* Has received corticosteroids at 2 mg/kg or higher for 3 weeks or longer as part of first-line therapy for aGVHD~* Has received systemic therapy other than corticosteroids for treatment of aGVHD as part of first-line therapy for acute GVHD; simultaneous uses of topical or enteric corticosteroids or psoralen plus ultraviolet A (PUVA) for first-line are permitted~* aGVHD after second hematopoietic cell transplantation (HCT) is excluded~* Karnofsky performance status =\< 50%~* Requiring mechanical ventilation or renal replacement therapy at the time of enrollment~* Histologic or flow-cytometric evidence of relapse or progression of underlying disease; molecular or cytogenetic presence of disease is permitted; mixed chimerism is permitted~* Current or prior diagnosis of chronic GVHD (classic or overlap) as defined by National Institutes of Health (NIH) consensus criteria~* Donor lymphocyte infusion (DLI)-induced aGVHD when DLI was given for progression of the underlying disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observational (medical chart review) (Type: None): Study data are collected and managed using REDCap tools at baseline and on days 5, 28, and 56.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Impact of Benzodiazepin Withdrawn After Curative Epilepsy Surgery in Children With Focal Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria :~* Children aged 6 years to 14 years and 10 months~* Epilepsy patients with drug-resistant focal epilepsy with programmed curative surgical management~* Subject with IQ greater than 70 (Evaluation of IQ in pre-surgical evaluation)~* Antiepileptic drug regimen comprising a benzodiazepine daily~* Subject beneficiary of French national social security scheme~* Parental (and the child if he or she is of age to do so) have signed the study consent~Exclusion Criteria:~* Patient unable to perform cognitive tests or unwilling to do them~* Planned change in drug regimen before the post-surgical period~* Denied to participate in the research

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Rapamycin for Prevention of Chronic Graft-Versus-Host Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Received an allogeneic MSD or MUD PBSCT~* 24 weeks post SCT~* Currently on Tacrolimus for GVHD prophylaxis~* Deemed eligible for tapering off of Tacrolimus by primary BMT physician~Exclusion Criteria:~* Relapsed Disease~* Ongoing GVHD~* Patients whose immunosuppression is being stopped early to treat or prevent relapse~* Patients with pure red cell aplasia due to ABO mismatched donor~* Ongoing thrombotic microangiopathy~* Allergy to rapamycin~* Women of childbearing potential must have a negative serum pregnancy test performed prior to the start of treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent Form~* Aged 3-5 years~* Diagnosis of cystic fibrosis~Exclusion Criteria:~* Children taking scheduled inhaled Pulmozyme or hypertonic saline within 56 days prior to Visit 1 or any Pulmozyme in the 28 days before Visit 1~* Involvement in a clinical intervention trial within the 4 weeks prior to Visit 1~* Use of an investigational drug or device within 28 days prior to Visit 1~* Any other condition that might increase the risk of participation to the patient in the judgement of the investigator

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Dornase alfa (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of the BrainPort™ Balance Device to Improve Balance in Bilateral Vestibular Hypofunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented history of acquired bilateral vestibular dysfunction for a duration of at least one year which has been unsuccessfully treated or reached a plateau with conventional vestibular rehabilitation.~* No greater than 2 successful attempts out of 6 on the NeuroCom Equitest Sensory Organization Tests 5 and 6.~* Failure on the Rotary Chair Vestibulo-ocular Reflex (VOR) Test as evidenced by a gain of less than or equal to -2 standard deviations at frequencies of .025, and .05 Hz.~* Normal corrected vision (20/40 or better).~* Able to read and understand the informed consent form, and willing to sign the informed consent form.~* Willing to complete all follow-up evaluations required by the study protocol.~* Able to stand for a period of 20 minutes in a stationary position with weight evenly distributed without moderate pain, muscle cramping or numbness in the lower extremities.~Exclusion Criteria:~* Neurological disorders other than bilateral vestibular disorder, as determined by medical history and neurological screening procedure.~* Current oral health problems as determined by health questionnaire and an examination of the oral cavity.~* Cigarette smokers and those who use chewing tobacco.~* Currently taking either benzodiazepine or barbiturate medication.~* Any medical condition as determined by the health questionnaire that would interfere with performance on the postural stability evaluation tests.~* Known neuropathies of tongue or skin tactile system.~* Peripheral neuropathies of the lower extremities.~* Prior exposure to BrainPort™ balance device (does not apply to control group subjects who cross over).~* Subjects who are unwilling or unable to adhere to all study requirements, including completion of the training period, evaluation tests, and return to clinic for a follow-up visit.~* Subjects who have undergone middle ear or other surgery with sacrifice or damage to the chorda tympani, lingual, or hypoglossal nerve.~* Subjects who have an implanted device such as a pacemaker or defibrillator.~* If the subject is female, she is pregnant.~* If the subject is unwilling to discontinue medications for dizziness or imbalance 48 hours prior to beginning the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Interest of the Smartphone Application MonCœur in the Follow-up of Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient hospitalized for acute or decompensated heart failure~* Patient with a smartphone and able to use a digital application~* Beneficiary of a social protection scheme~* Patients benefiting from a telemedicine program can be included~Exclusion Criteria:~* Acute coronary syndrome during ongoing hospitalization.~* Acute myocarditis, constrictive pericarditis, acute endocarditis during ongoing hospitalization.~* Isolated right heart failure of respiratory origin.~* Existence of a cause considered rapidly reversible to acute heart failure: tachyarrhythmia, excessive bradycardia, acute anemia, acute renal failure, malignant hypertension, overdose or cardiotoxic drug intoxication.~* Indication of cardiac surgery scheduled within 3 months after hospitalization, patients with Tavi or MItraclip expected within 3 months~* Extracardiac disease with short-term prognosis (progressive neoplasia).~* Refusal or incapacitation of language or psychic to sign informed consent~* Patients participating in an other biomedical research can not participate in this study for the first 6 months, not to interfere with the consultation process of the study.~* Pregnant or lactating women can't participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APPLI (Type: EXPERIMENTAL): Care support with implementation of the application
- CONTROL (Type: NO_INTERVENTION): Conventional care support

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues